Press Release: Stemvax : Innovest Global Inc. Signs Letter of Intent to Acquire 20% of StemVax Therapeutics, a Biotechnology & Health Sciences Company

CLEVELAND, March 19, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC PINK: IVST) announces it has signed a Letter of Intent to acquire a 20% stake in StemVax LLC. StemVax is a Translational Biotechnology Company that is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors.